Chemours Company (The) (CC)

Chemours Company (The)'s Q·Score is 4/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. 56% of 9 covering analysts have a positive rating. Key area to monitor: currently unprofitable (-7% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for CC is $22.67, based on ratings from 9 Wall Street analysts. This is 18.3% below the current price of $27.73. Price targets are forward-looking estimates and not guarantees of future performance.

Chemours Company (The) (CC) scores below peers on valuation metrics, trading above typical sector multiples. Its forward P/E ratio stands at 12.1×. The consensus analyst price target of $22.67 is 18% below the current price.

Chemours Company (The) is scheduled to report earnings in 2 days, on May 5, 2026.

Chemours Company (The) has a net profit margin of -6.6%, indicating the company is currently operating at a net loss. Its gross margin stands at 15.7%, reflecting a more cost-intensive business model.

Chemours Company (The) currently offers a dividend yield of 1.26%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.

Chemours Company (The) is reporting revenue declining 2.1% year-over-year.

Chemours Company (The) has a debt-to-equity ratio of 17.51×, reflecting a high debt-to-equity ratio, which increases financial risk especially in rising rate environments. Its current ratio is 1.78×, indicating comfortable short-term liquidity.